Last reviewed · How we verify

Joint pain — Treatment Landscape & Competitive Intelligence

Joint pain (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Joint pain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Aleve naproxen Generic (originally Syntex) NSAID Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1 1976-01-01
Acetaminophen Paracetamol Polymedica acetaminophen Transient receptor potential cation channel subfamily V member 4 1968-01-01
Norgesic acetylsalicylic acid Endo centrally acting muscle relaxant with anticholinergic properties reticular formation (brain stem) 1950-01-01
Norgesic caffeine Hikma Central Nervous System Stimulant [EPC] Adenosine receptor A2a 1948-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Joint pain
  2. Endo · 1 drug in Joint pain
  3. Generic (originally Syntex) · 1 drug in Joint pain
  4. Hikma · 1 drug in Joint pain
  5. Polymedica · 1 drug in Joint pain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Joint pain:

Cite this brief

Drug Landscape (2026). Joint pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/joint-pain. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing